Mylan; which is based in the United States, has recently launched the authorized generic version of EpiPen (epinephrine injection, USP) auto-injector. This comes following the criticism of the recent price hike.
The auto-injecting (self-injectable device) contains epinephrine. Epinephrine is the first-line treatment for life-threatening allergic reactions also known as anaphylaxis.
The authorized generic which is expected to reach pharmacies in the beginning of next week, has the same drug formula and device functionality as EpiPen auto-injector and it is administered in the same way.
Mylan CEO Heather Bresch stated: “Americans are rightfully concerned about rising drug prices and now more than ever patients and families across this country are standing at the pharmacy counter struggling to pay for their medications.”
“Pharmaceutical pricing is too far removed from the patient at the pharmacy counter and not designed for today’s increasingly consumerized healthcare system.”
“While it is important to understand the outdated and complex system that determines what someone pays for medicine in the United States, hardworking families do not need an explanation, they need a solution.”
The authorized generic for EpiPen auto-injector; which is available in strengths of 0.15mg and 0.3mg, is soon planning to be launched in retail stores. This should help ease the burden placed on patients due to the recent rising drug prices related to the EpiPen auto-injector.
Bresch added: “Unfortunately, families will continue to face sticker shock for medications and may be forced to make difficult choices until the pharmaceutical pricing system is reformed to address the increasing shift of costs directly to consumers.”
Mylan is a company which began in West Virginia over 55 years ago. Currently its medicines fill out one in thirteen prescriptions in all of the United States, equaling to 21 billion doses.